Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Bullboard Posts
Comment by df2830on Jun 21, 2016 4:28pm
92 Views
Post# 24984936

RE:RE:RE:RE:RE:RE:Great News Today

RE:RE:RE:RE:RE:RE:Great News Today@retiredcop and the other regulars.....Been here quietly at $0.095 for a little over a month or so, and reading your posts now and then.  Thank you all for the civil and informative dialogue - although, as you can start to see by the sudden barrage of posts from all the new geniuses, I'm afraid that may have changed today :-).  

I agree that this wasn't block buster news, but what it does do is validate their approach even further to the point where perhaps, just perhaps, a tipping point in credibility, or the first of many tipping points in credibility, has been breached.  That's why the violent reaction upwards.  I posted this morning that we might not break $0.12 today, but that it would be a good time to buy more at .11.  I actually followed my own advice and did buy a bit more at .11.  The subsequent action did surprise me as well, pleasantly to say the least.  GL and thanks again for the good reads.
Bullboard Posts